Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Scynexis Inc (SCYX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 82,744
  • Shares Outstanding, K 50,148
  • Annual Sales, $ 260 K
  • Annual Income, $ -12,470 K
  • 60-Month Beta 2.38
  • Price/Sales 314.16
  • Price/Cash Flow N/A
  • Price/Book 2.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.19
  • Low Estimate -0.20
  • Prior Year -0.12
  • Growth Rate Est. (year over year) -66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.41 +17.02%
on 03/28/19
1.90 -13.16%
on 04/09/19
+0.03 (+1.85%)
since 03/18/19
3-Month
0.67 +146.27%
on 01/30/19
1.90 -13.16%
on 04/09/19
+0.91 (+122.97%)
since 01/18/19
52-Week
0.35 +371.43%
on 12/21/18
2.15 -23.26%
on 07/12/18
+0.40 (+32.00%)
since 04/18/18

Most Recent Stories

More News
SCYNEXIS to Discuss ECCMID 2019 Clinical Data, Including Successful Case Studies in Candida auris and Other Difficult-to-Treat Infections, on Conference Call

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced results showing evidence of activity...

SCYX : 1.65 (+2.48%)
Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that twelve of its member companies...

MLNT : 4.33 (+1.41%)
ETTX : 5.50 (-13.52%)
ITRM : 8.18 (-4.10%)
CFRX : 0.53 (-10.07%)
MTFB : 2.12 (-3.20%)
SMMT : 1.91 (-1.55%)
SCYX : 1.65 (+2.48%)
CDTX : 2.38 (-1.65%)
NBRV : 2.72 (+2.26%)
PRTK : 5.57 (unch)
SCYNEXIS Commends the New York Times for its Reporting on Candida auris and Other Drug-Resistant Pathogens

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today commended the New York Times for its reporting...

SCYX : 1.65 (+2.48%)
SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study, in Data to be Presented at the 29th ECCMID

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced data demonstrating the potential use...

SCYX : 1.65 (+2.48%)
SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the...

SCYX : 1.65 (+2.48%)
SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the year ended...

SCYX : 1.65 (+2.48%)
ZYNE : 8.09 (-1.70%)
SCYNEXIS is Retiring Existing Term Loan Through a Lower-Interest and Longer-Term Convertible Note

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the sale of a $16.0 million aggregate...

SCYX : 1.65 (+2.48%)
SLRC : 21.29 (-0.56%)
Various Industries Search for a Solution to the Spread of Infectious Diseases

The need for sanitization and disinfection is growing, not only in the medical industry but across many other sectors as well. In particular, the medical segment is the biggest driver for the market because...

OGEN : 0.50 (-2.27%)
TTOO : 2.52 (-4.55%)
DVAX : 6.41 (-0.31%)
SCYX : 1.65 (+2.48%)
PCTL : 0.1400 (+2.94%)
SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present new in...

SCYX : 1.65 (+2.48%)
Disinfectant Technology in Demand by Food Processors

Infectious diseases were ranked in the top ten causes of deaths worldwide in 2016, according to the World Health Organization. These diseases are spread by organisms through direct or even indirect contact....

PPC : 25.82 (+0.27%)
DANOY : 15.8201 (+0.80%)
SCYX : 1.65 (+2.48%)
OMI : 3.38 (-6.63%)
PCTL : 0.1400 (+2.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade SCYX with:

Business Summary

SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening...

See More

Key Turning Points

2nd Resistance Point 1.78
1st Resistance Point 1.71
Last Price 1.65
1st Support Level 1.59
2nd Support Level 1.54

See More

52-Week High 2.15
Last Price 1.65
Fibonacci 61.8% 1.46
Fibonacci 50% 1.25
Fibonacci 38.2% 1.04
52-Week Low 0.35

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar